Results 1 to 10 of about 487,050 (179)

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies [PDF]

Frontiers in Immunology, 2019
Heavy chain-only antibodies (HCAbs) do not associate with light chains and their VH regions are functional as single domains, forming the smallest active antibody fragment.
Starlynn C. Clarke, Biao Ma, Nathan D. Trinklein, Ute Schellenberger, Michael J. Osborn, Laure-Hélène Ouisse, Andrew Boudreau, Laura M. Davison, Katherine E. Harris, Harshad S. Ugamraj, Aarti Balasubramani, Kevin H. Dang, Brett Jorgensen, Heather Anne N. Ogana, Duy T. Pham, Payal P. Pratap, Preethi Sankaran, Ignacio Anegon, Wim C. van Schooten, Marianne Brüggemann, Roland Buelow, Shelley Force Aldred   +21 more
doaj   +2 more sources

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies

mAbs, 2023
Upon reformatting of an antibody to single-chain variable fragment format, a region in the former variable/constant domain interface of the heavy chain becomes accessible for preexisting (PE) anti-drug antibody (ADA) binding.
Maria U. Johansson, Christopher Weinert, Dietrich Alexander Reichardt, Dana Mahler, Dania Diem, Christian Hess, Diana Feusi, Simon Carnal, Julia Tietz, Noreen Giezendanner, Fabio Mario Spiga, David Urech, Stefan Warmuth   +12 more
doaj   +1 more source

Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics

mAbs, 2022
Immunoglobulin G (IgG) has served as a traditional framework for antibody-based biology, and engineering approaches for creating multispecific therapeutics have greatly expanded its applicability.
Florian Heinkel, Meghan M. Verstraete, Siran Cao, Janessa Li, Patrick Farber, Elizabeth Stangle, Begonia Silva-Moreno, Fangni Peng, Surjit Dixit, Martin J. Boulanger, Thomas Spreter Von Kreudenstein, Eric Escobar-Cabrera   +11 more
doaj   +1 more source

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

Design and Characterization of Bispecific and Trispecific Antibodies Targeting SARS-CoV-2

Vaccines
Background/Objectives: COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic since its outbreak in 2019. As an increasing number of variants have emerged, especially concerning variants such as Omicron BA.1, BA.2, XBB.1, EG.5, which can escape
Jiayang Wang, Qi Qian, Yushan Jiang, Zuxin Liang, Yun Peng, Wei Zhao, Yang Yang, Chenguang Shen   +7 more
doaj   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities

mAbs, 2022
Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the ...
Desislava Yanakieva, Lukas Pekar, Andreas Evers, Markus Fleischer, Stephan Keller, Dirk Mueller-Pompalla, Lars Toleikis, Harald Kolmar, Stefan Zielonka, Simon Krah   +9 more
doaj   +1 more source

A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour‐targeting function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier, Sandra Szu‐Wei Hwang, Anthony F. Rullo   +2 more
wiley   +1 more source

Highly sensitive detection of antibody nonspecific interactions using flow cytometry

mAbs, 2021
The rapidly evolving nature of antibody drug development has resulted in technologies that generate vast numbers (hundreds to thousands) of lead antibody candidates during early discovery.
Emily K. Makowski, Lina Wu, Alec A. Desai, Peter M. Tessier   +3 more
doaj   +1 more source